

Oleksii Korzh

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/879638/oleksii-korzh-publications-by-year.pdf>

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

49
papers

13,565
citations

26
h-index

89
g-index

89
ext. papers

17,024
ext. citations

13.3
avg, IF

6.07
L-index

#	Paper	IF	Citations
49	Diabetes mortality and trends before 25 years of age: an analysis of the Global Burden of Disease Study 2019.. <i>Lancet Diabetes and Endocrinology</i> , 2022 ,	18.1	4
48	CYTOKINES AS MEDIATORS OF THE IMMUNE SYSTEM AND THEIR ROLE IN THE PATHOGENESIS OF COMMUNITY-ACQUIRED PNEUMONIA. <i>World of Medicine and Biology</i> , 2021 , 17, 33	0.2	1
47	EU-Wide Cross-Sectional Observational Study of Lipid-Modifying Therapy Use in Secondary and Primary Care: the DA VINCI study. <i>European Journal of Preventive Cardiology</i> , 2021 , 28, 1279-1289	3.9	92
46	The study of fibroblast growth factor-2, sulfated glycosaminoglycans and oxyproline with mitral valve prolapse in combination with type 1 diabetes mellitus. <i>EUREKA Health Sciences</i> , 2021 , 9-15	0.1	
45	Effect of SGLT2 Inhibitors on Stroke and Atrial Fibrillation in Diabetic Kidney Disease: Results From the CREDENCE Trial and Meta-Analysis. <i>Stroke</i> , 2021 , 52, 1545-1556	6.7	11
44	Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure. <i>New England Journal of Medicine</i> , 2021 , 384, 105-116	59.2	164
43	Interleukin 6 and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Chronic Coronary Syndrome. <i>JAMA Cardiology</i> , 2021 ,	16.2	5
42	Renal, Cardiovascular, and Safety Outcomes of Canagliflozin by Baseline Kidney Function: A Secondary Analysis of the CREDENCE Randomized Trial. <i>Journal of the American Society of Nephrology: JASN</i> , 2020 , 31, 1128-1139	12.7	51
41	Prediction of Residual Risk by Ceramide-Phospholipid Score in Patients With Stable Coronary Heart Disease on Optimal Medical Therapy. <i>Journal of the American Heart Association</i> , 2020 , 9, e015258	6	20
40	Clinical and pathogenetic rationale for the prevention and treatment of obesity. <i>Shidnoevropejskij Zurnal Vnutrisnoi Ta Simejnoi Medicini</i> , 2020 , 2020, 146-152	0.1	
39	State of Connective Tissue Metabolism in Mitral Valve Prolapse in Combination with Type 1 Diabetes Mellitus. <i>Ukrainskij žurnal Medicini Biologična Sportu</i> , 2020 , 5, 189-195	0.1	
38	Self-management Education in Type 2 Diabetes in Primary Care. <i>Folia Medica</i> , 2020 , 62, 525-531	0.5	
37	Knowledge and Application of Cardiovascular Disease Prevention Guidelines among Family Physicians: A Cross-sectional Study. <i>Open Access Macedonian Journal of Medical Sciences</i> , 2020 , 9, 990-995 ¹		
36	Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: GALACTIC-HF baseline characteristics and comparison with contemporary clinical trials. <i>European Journal of Heart Failure</i> , 2020 , 22, 2160-2171	12.3	24
35	Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. <i>New England Journal of Medicine</i> , 2019 , 380, 2295-2306	59.2	2060
34	Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups. <i>Circulation</i> , 2019 , 140, 739-750 ¹	16.7	140
33	The impact of governance in primary health care delivery: a systems thinking approach with a European panel. <i>Health Research Policy and Systems</i> , 2019 , 17, 65	3.7	10

32	Improving the drug compliance of hypertensive patients in primary care: importance of health education and self-management. <i>Archives of the Balkan Medical Union</i> , 2019 , 54, 594-507	0.4	2
31	The Prevention of Cardiovascular Diseases in Diabetes Mellitus: Role of Glycemic Control. <i>Family Medicine</i> , 2019 , 76-79	0.1	
30	Managing type 2 diabetes mellitus: Role of family physicians in successful treatment goal achievement. <i>Electronic Journal of General Medicine</i> , 2019 , 16, em146	2.1	
29	Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial. <i>Lancet Respiratory Medicine</i> , 2019 , 7, 46-59	35.1	138
28	Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. <i>New England Journal of Medicine</i> , 2017 , 376, 1713-1722	59.2	2700
27	Inflammatory Biomarkers Interleukin-6 and C-Reactive Protein and Outcomes in Stable Coronary Heart Disease: Experiences From the STABILITY (Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy) Trial. <i>Journal of the American Heart Association</i> , 2017 , 6,	6	105
26	Self-Reported Health and Outcomes in Patients With Stable Coronary Heart Disease. <i>Journal of the American Heart Association</i> , 2017 , 6,	6	4
25	Clinical Efficacy and Safety of Evolocumab in High-Risk Patients Receiving a Statin: Secondary Analysis of Patients With Low LDL Cholesterol Levels and in Those Already Receiving a Maximal-Potency Statin in a Randomized Clinical Trial. <i>JAMA Cardiology</i> , 2017 , 2, 1385-1391	16.2	62
24	The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics. <i>American Journal of Nephrology</i> , 2017 , 46, 462-472	4.6	149
23	Angiotensin-Converting Enzyme Inhibitor Use and Major Cardiovascular Outcomes in Type 2 Diabetes Mellitus Treated With the Dipeptidyl Peptidase 4 Inhibitor Alogliptin. <i>Hypertension</i> , 2016 , 68, 606-13	8.5	18
22	The prevalence of comorbidities in COPD patients, and their impact on health status and COPD symptoms in primary care patients: a protocol for an UNLOCK study from the IPCRG. <i>Npj Primary Care Respiratory Medicine</i> , 2016 , 26, 16069	3.2	2
21	Cardiorenal Syndrome in Patients with Chronic Kidney Disease and Ischemic Heart Disease. <i>Polki</i> , 2016 , 45-51	0.3	2
20	Significance of education and self-management support for patients with chronic heart failure in family physician practice. <i>Family Medicine and Primary Care Review</i> , 2016 , 4, 432-436	0.6	3
19	Effects of the lercanidipine-enalapril combination vs. the corresponding monotherapies on home blood pressure in hypertension: evidence from a large database. <i>Journal of Hypertension</i> , 2016 , 34, 139-48	1.9	8
18	Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. <i>Lancet, The</i> , 2015 , 385, 2067-76	4.0	551
17	Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors. <i>New England Journal of Medicine</i> , 2015 , 372, 211-21	59.2	376
16	We must join forces in the battle against COPD. <i>European Respiratory Journal</i> , 2015 , 46, 1526-8	13.6	
15	Darapladib for preventing ischemic events in stable coronary heart disease. <i>New England Journal of Medicine</i> , 2014 , 370, 1702-11	59.2	363

14	Ivabradine in stable coronary artery disease without clinical heart failure. <i>New England Journal of Medicine</i> , 2014 , 371, 1091-9	59.2	315
13	Alogliptin after acute coronary syndrome in patients with type 2 diabetes. <i>New England Journal of Medicine</i> , 2013 , 369, 1327-35	59.2	1858
12	Tiotropium Respimat inhaler and the risk of death in COPD. <i>New England Journal of Medicine</i> , 2013 , 369, 1491-501	59.2	270
11	Rivaroxaban for thromboprophylaxis in acutely ill medical patients. <i>New England Journal of Medicine</i> , 2013 , 368, 513-23	59.2	424
10	Long-term safety and efficacy of empagliflozin, sitagliptin, and metformin: an active-controlled, parallel-group, randomized, 78-week open-label extension study in patients with type 2 diabetes. <i>Diabetes Care</i> , 2013 , 36, 4015-21	14.6	159
9	Single-pill combination of telmisartan/amlodipine in patients with severe hypertension: results from the TEAMSTA severe HTN study. <i>Journal of Clinical Hypertension</i> , 2012 , 14, 206-15	2.3	30
8	Tiotropium versus salmeterol for the prevention of exacerbations of COPD. <i>New England Journal of Medicine</i> , 2011 , 364, 1093-1103	59.2	499
7	Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial. <i>Diabetes, Obesity and Metabolism</i> , 2011 , 13, 928-38	6.7	302
6	Beclomethasone/formoterol in the management of COPD: a randomised controlled trial. <i>Respiratory Medicine</i> , 2010 , 104, 1858-68	4.6	84
5	Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. <i>Lancet, The</i> , 2010 , 376, 875-85	40	1646
4	Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2008 , 372, 807-16	40	775
3	The BEAUTIFUL study: randomized trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction - baseline characteristics of the study population. <i>Cardiology</i> , 2008 , 110, 271-82	1.6	33
2	IPCRG Consensus statement: tackling the smoking epidemic - practical guidance for primary care. <i>Primary Care Respiratory Journal: Journal of the General Practice Airways Group</i> , 2008 , 17, 185-93		22
1	Analysis of the placebo response to the therapeutic environment. <i>IOP Conference Series: Earth and Environmental Science</i> , 2013 , 635, 012013	0.3	